Short Interest in Theratechnologies Inc. (NASDAQ:THTX) Rises By 94.4%

Theratechnologies Inc. (NASDAQ:THTX) was the recipient of a significant growth in short interest in April. As of April 15th, there was short interest totalling 24,100 shares, a growth of 94.4% from the March 31st total of 12,400 shares. Based on an average daily volume of 49,100 shares, the short-interest ratio is currently 0.5 days. Approximately 0.1% of the shares of the company are sold short.

Hedge Funds Weigh In On Theratechnologies

A number of hedge funds have recently made changes to their positions in the business. Summit Trail Advisors LLC acquired a new stake in Theratechnologies during the 1st quarter valued at $55,000. AIGH Capital Management LLC grew its holdings in Theratechnologies by 362.9% during the 4th quarter. AIGH Capital Management LLC now owns 3,719,302 shares of the company’s stock valued at $6,025,000 after purchasing an additional 2,915,906 shares in the last quarter. Worth Venture Partners LLC grew its holdings in Theratechnologies by 362.5% during the 4th quarter. Worth Venture Partners LLC now owns 906,557 shares of the company’s stock valued at $1,469,000 after purchasing an additional 710,551 shares in the last quarter. Wealthspire Advisors LLC acquired a new stake in Theratechnologies during the 4th quarter valued at $83,000. Finally, National Bank of Canada FI grew its holdings in Theratechnologies by 65.4% during the 4th quarter. National Bank of Canada FI now owns 113,378 shares of the company’s stock valued at $191,000 after purchasing an additional 44,825 shares in the last quarter.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald restated an “overweight” rating on shares of Theratechnologies in a research report on Friday, January 12th.

Theratechnologies Price Performance

Shares of THTX remained flat at $1.30 on Friday. 12,985 shares of the company traded hands, compared to its average volume of 20,393. The stock has a market cap of $31.46 million, a price-to-earnings ratio of -2.13 and a beta of 1.34. Theratechnologies has a fifty-two week low of $0.88 and a fifty-two week high of $4.30. The firm has a 50-day moving average price of $1.42 and a 200 day moving average price of $1.53.

Theratechnologies (NASDAQ:THTX) last posted its quarterly earnings results on Wednesday, February 21st. The company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.16. The company had revenue of $23.45 million for the quarter. During the same quarter in the prior year, the company posted ($0.36) earnings per share. On average, sell-side analysts expect that Theratechnologies will post -0.03 earnings per share for the current fiscal year.

About Theratechnologies

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.